

**PHYTOTECHNOLOGY | GOOGLE PILLS | VEGAN, ORGANIC | HYPOTHESIS |  
FOR RESEARCH ONLY, DON'T TRY AT HOME**

**THIRD-PARTY APP, NOT AN OFFICIAL GOOGLE APP**

**DIAGNOSTIC PROPOSAL: BRAIN CANCER | PI: MARIE-SOLEIL SESHAT LANDRY**

# **BRAIN CANCER**

**Preprint Server ID: GP-PI-3.1-2026-BRA**

**Date: January 18, 2026**

**Subject Category: Bio-Informatics / Integrative Research**

## **SOVEREIGN VEGAN ORGANIC PHYTO- MODULATION OF BRAIN CANCER: A GOOGLE PILLS PHYTOINTELLIGENCE 3.1 PROPOSED PROTOCOL**

---

**Principal Investigator: Marie-Soleil Seshat LAndry**

**Affiliation: Independent Research Initiative / Google Pills PhytoIntelligence User Group**

**Preprint ID: GP-PI-3.1-2026-BRA**

**Date:** January 18, 2026

**Title:** BRAIN CANCER

---

 1. CRITICAL DISCLAIMER (FOR RESEARCH ONLY, DON'T TRY AT HOME)

**WARNING:** The content presented in this manuscript is for theoretical research, educational, and informational purposes only. It constitutes a preliminary draft for scientific review and **does not** constitute medical advice, diagnosis, or treatment. The protocols described herein involve phytochemical interactions that may contraindicate with standard chemotherapy, radiotherapy, or immunotherapy. The blood-brain barrier (BBB) presents unique pharmacokinetic challenges; layman experimentation can lead to severe neurotoxicity or fatal interactions. Always consult a qualified oncologist or neuro-specialist before altering any health regimen.

 2. THIRD-PARTY NOTICE

This manuscript describes an independent research initiative utilizing the "Google Pills" theoretical framework. This work is not affiliated with, endorsed by, or sponsored by Google LLC or any specific pharmaceutical entity. The "Google Pills" nomenclature refers to a specific algorithmic approach to phytochemical database indexing and is used here as a descriptor of the methodology, not a commercial product.

3. ABSTRACT

Glioblastoma multiforme (GBM) and other high-grade gliomas represent a therapeutic challenge due to the blood-brain barrier (BBB) and a highly immunosuppressive tumor microenvironment (TME). This study explores a multi-targeted phytochemical protocol designed to modulate the inflammatory cascade driving tumorigenesis. Specifically, we investigate the suppression of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway and the subsequent downregulation of pro-inflammatory cytokines, specifically Interleukin-1 beta (IL-1β) and Tumor Necrosis Factor-alpha (TNF-α). By concurrently activating the NRF<sub>2</sub> antioxidant pathway, this protocol aims to induce oxidative stress specifically within tumor cells while

protecting healthy neuronal tissue, offering a novel metabolic deconvolution of brain cancer progression.

#### 4. INTRODUCTION: DECONVOLUTION OF THE DIAGNOSTIC

To address the complexity of brain malignancies, we deconstruct the pathology into four distinct, manageable biological targets. This deconvolution allows for a modular therapeutic approach:

1. **The Blood-Brain Barrier (BBB) Impermeability:** The primary obstacle preventing systemic therapies from reaching the tumor site in effective concentrations.
2. **The NF- $\kappa$ B Inflammatory Loop:** Constitutive activation of NF- $\kappa$ B in glioma cells drives proliferation, survival, and invasion, fueled by IL-1 $\beta$  and TNF- $\alpha$ .
3. **Oxidative Stress & Hypoxia:** Tumors thrive in hypoxic environments; manipulating Reactive Oxygen Species (ROS) can trigger apoptosis in cancer cells that lack adequate antioxidant defense.
4. **Angiogenic Dysregulation:** The rapid formation of abnormal blood vessels that supply the tumor, often driven by inflammatory signaling.


#### 5. MECHANISM OF ACTION


The proposed mechanism relies on the antagonistic crosstalk between two master transcriptional regulators: **NRF<sub>2</sub>** (Nuclear factor erythroid 2-related factor 2) and **NF- $\kappa$ B**.

- **NF- $\kappa$ B Suppression:** In the context of brain cancer, the canonical NF- $\kappa$ B pathway is hyperactive. This results in the excessive release of TNF- $\alpha$  and IL-1 $\beta$ , which act as autocrine signals to promote tumor growth and immune evasion. The protocol utilizes specific lipophilic phytochemicals to inhibit the phosphorylation of I $\kappa$ B (the inhibitor of NF- $\kappa$ B), thereby trapping NF- $\kappa$ B in the cytoplasm and preventing the transcription of survival genes.
- **NRF<sub>2</sub> Activation:** Simultaneously, the protocol seeks to activate NRF<sub>2</sub>. While NRF<sub>2</sub> can sometimes protect cancer cells, distinct pulsatile activation has been shown to restore redox homeostasis in the TME. The goal is to re-sensitize glioma cells to apoptosis by overwhelming their distinct metabolic machinery while protecting healthy glial cells from inflammation-induced damage.

#### 6. VISUALIZING MOLECULAR DECONVOLUTION

Phyto-Protocol Ingestion





## 7. MATERIALS: THE GOOGLE PILLS PHYTO-PROTOCOL

The following table outlines the specific phytochemical agents selected for their BBB permeability and documented ability to modulate the NF- $\kappa$ B/NRF<sub>2</sub> axis.

| COMPOUND                   | TARGET MECHANISM                                                      | PRIMARY SOURCE           | EVIDENCE (PMID)                                                                                                                                                                   |
|----------------------------|-----------------------------------------------------------------------|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Curcumin (Micellar)</b> | Inhibits NF- $\kappa$ B; downregulates TNF- $\alpha$ and IL-1 $\beta$ | <i>Curcuma longa</i>     | [PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/18462866/">18462866</a> ]<br>( <a href="https://pubmed.ncbi.nlm.nih.gov/18462866/">https://pubmed.ncbi.nlm.nih.gov/18462866</a> ) |
| <b>Resveratrol</b>         | Activates NRF <sub>2</sub> ; crosses BBB; induces apoptosis           | <i>Vitis vinifera</i>    | [PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/29986423/">29986423</a> ]<br>( <a href="https://pubmed.ncbi.nlm.nih.gov/29986423/">https://pubmed.ncbi.nlm.nih.gov/29986423</a> ) |
| <b>Sulforaphane</b>        | Potent NRF <sub>2</sub> inducer; reduces oxidative stress             | <i>Brassica oleracea</i> | [PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/25738875/">25738875</a> ]<br>( <a href="https://pubmed.ncbi.nlm.nih.gov/25738875/">https://pubmed.ncbi.nlm.nih.gov/25738875</a> ) |
| <b>EGCG</b>                | Inhibits                                                              | <i>Camellia</i>          | [PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/23092292/">23092292</a> ]                                                                                                         |

|                        |                                                         |                          |                                                                                                                                                                                 |
|------------------------|---------------------------------------------------------|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                        | metalloproteinases;<br>modulates<br>signaling           | <i>sinensis</i>          | ( <a href="https://pubmed.ncbi.nlm.nih.gov/23092292">https://pubmed.ncbi.nlm.nih.gov/23092292</a> )                                                                             |
| <b>Boswellic Acids</b> | 5-LOX inhibition;<br>reduces cerebral<br>edema          | <i>Boswellia serrata</i> | [PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/21287538">21287538</a> ]<br>( <a href="https://pubmed.ncbi.nlm.nih.gov/21287538">https://pubmed.ncbi.nlm.nih.gov/21287538</a> ) |
| <b>Quercetin</b>       | Flavonoid<br>antioxidant;<br>disrupts Hsp <sub>70</sub> | <i>Sophora japonica</i>  | [PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/28830214">28830214</a> ]<br>( <a href="https://pubmed.ncbi.nlm.nih.gov/28830214">https://pubmed.ncbi.nlm.nih.gov/28830214</a> ) |

## 8. FALSIFICATION STRATEGY

To ensure scientific rigor, this study adopts a falsificationist approach based on the null hypothesis ( $H_0$ ).

- **Null Hypothesis ( $H_0$ ):** The administration of the Phyto-Protocol results in **no statistically significant difference** in the reduction of IL-1 $\beta$  or TNF- $\alpha$  levels, nor in tumor volume reduction, compared to the placebo control group ( $p > 0.05$ ).
- **Falsification Criteria:** The hypothesis of efficacy is considered falsified if the experimental group shows a p-value  $> 0.05$  in proliferation assays or if the confidence interval (CI) of cytokine reduction crosses zero.
- **Adverse Event Threshold:** Any increase in neurological deficit scores (NEDS)  $> 20\%$  compared to baseline will necessitate immediate rejection of the protocol regardless of anti-tumor efficacy.

## 9. CONCLUSION

This manuscript outlines a theoretical framework for a combinatorial phytochemical intervention in brain cancer. By focusing on the deconvolution of the NF- $\kappa$ B and NRF<sub>2</sub> signaling pathways, we propose a strategy to bypass the limitations of current monotherapies. The reduction of inflammatory cytokines IL-1 $\beta$  and TNF- $\alpha$  serves as the primary biomarker for efficacy. While promising in mechanistic theory, rigorous in vitro and in vivo validation is required to reject the null hypothesis and establish a safety profile suitable for human trials. Future work will focus on the nano-encapsulation of

these compounds to further enhance blood-brain barrier penetration.